Recce Pharmaceuticals (ASX:RCE) Other Stockholders Equity: A$-0.00 Mil (As of Dec. 2025)


ASX:RCE Recce Pharmaceuticals Ltd ASX:RCE
31 GF Score
Price A$0.38
! 4 Warning Signs
View Full Analysis

What is Recce Pharmaceuticals Other Stockholders Equity?

Recce Pharmaceuticals ASX:RCE -6.17% 31 Other Stockholders Equity is A$-0.00 Mil as of Dec. 2025. GuruFocus rates ASX:RCE with a GF Score™ of 31/100. The stock has 4 warning signs investors should review.

Recce Pharmaceuticals's Other Stockholders Equity for the quarter that ended in Dec. 2025 was A$-0.00 Mil.

Recce Pharmaceuticals's quarterly Other Stockholders Equity increased from Dec. 2024 (A$0.00 Mil) to Jun. 2025 (A$0.00 Mil) but then declined from Jun. 2025 (A$0.00 Mil) to Dec. 2025 (A$-0.00 Mil).

Recce Pharmaceuticals's annual Other Stockholders Equity increased from Jun. 2023 (A$-0.00 Mil) to Jun. 2024 (A$-0.00 Mil) and increased from Jun. 2024 (A$-0.00 Mil) to Jun. 2025 (A$0.00 Mil).

Recce Pharmaceuticals Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Recce Pharmaceuticals's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Recce Pharmaceuticals Other Stockholders Equity Chart

Recce Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -0.00 -0.00 -0.00 0.00

Recce Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 0.00 0.00 -0.00
ASX:RCE
31GF Score
Recce Pharmaceuticals Ltd ASX:RCE
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Recce Pharmaceuticals Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of A$-0.00 Mil mean?
Recce Pharmaceuticals (ASX:RCE) has a Other Stockholders Equity of A$-0.00 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Recce Pharmaceuticals and its competitors.
Is Recce Pharmaceuticals' Other Stockholders Equity too high?
Recce Pharmaceuticals' current Other Stockholders Equity is A$-0.00 Mil. Overall, Recce Pharmaceuticals has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Recce Pharmaceuticals' Other Stockholders Equity compare to VRTX and REGN?
Recce Pharmaceuticals' Other Stockholders Equity of A$-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Recce Pharmaceuticals and its competitors. Recce Pharmaceuticals's current Other Stockholders Equity is A$-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recce Pharmaceuticals stock overvalued right now?
Recce Pharmaceuticals (ASX:RCE) has a current Other Stockholders Equity of A$-0.00 Mil. The current Other Stockholders Equity is A$-0.00 Mil. Recce Pharmaceuticals' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Recce Pharmaceuticals (ASX:RCE), the current Other Stockholders Equity is A$-0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Recce Pharmaceuticals Business Description

Other Exchanges R9Q:Germany
Address 3 Brodie Hall Drive, Suite 10, Technology Park, Bentley, WA, AUS, 6102
Recce Pharmaceuticals Ltd is an Australia-based, globally-focused biotechnology company that is pioneering the development and commercialisation of a drug discovery and development business commercialising new Classes of synthetic anti-infectives with broad-spectrum activity designed to address the urgent health threat of antibiotic-resistant superbugs and emerging viral pathogens. Its patented candidate, RECCE 327, has been developed for the treatment of life-threatening bacterial infections. It has one segment, which is the research and development of pharmaceutical drugs. Geographic segments are Australia, the UK, and the USA, of which the majority of the revenue comes from Australia. It offers antibiotic drugs to treat bacterial infections for Sepsis, Escherichia coli, and Others.
31GF Score

Get the complete analysis for ASX:RCE

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.38
Price